Paul Josephs Buys 17,000 Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock

Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs purchased 17,000 shares of the company’s stock in a transaction dated Wednesday, January 8th. The stock was purchased at an average cost of $5.74 per share, for a total transaction of $97,580.00. Following the transaction, the chief executive officer now owns 559,717 shares of the company’s stock, valued at approximately $3,212,775.58. This trade represents a 3.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Lifecore Biomedical Stock Down 1.9 %

Shares of LFCR stock opened at $5.80 on Friday. Lifecore Biomedical, Inc. has a 12 month low of $3.68 and a 12 month high of $8.90. The company has a quick ratio of 0.80, a current ratio of 1.83 and a debt-to-equity ratio of 12.90. The firm has a market cap of $213.60 million, a PE ratio of 72.50 and a beta of 0.98. The stock has a 50 day moving average of $7.05 and a 200-day moving average of $5.82.

Lifecore Biomedical (NASDAQ:LFCR) last released its earnings results on Thursday, January 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.02. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%. On average, equities analysts predict that Lifecore Biomedical, Inc. will post -0.99 EPS for the current year.

Institutional Investors Weigh In On Lifecore Biomedical

Hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC acquired a new position in Lifecore Biomedical in the 2nd quarter valued at approximately $56,000. Creative Planning acquired a new position in shares of Lifecore Biomedical in the third quarter valued at $69,000. Public Employees Retirement System of Ohio bought a new position in Lifecore Biomedical in the third quarter worth $119,000. Rhumbline Advisers boosted its stake in Lifecore Biomedical by 1,668.5% during the second quarter. Rhumbline Advisers now owns 26,899 shares of the company’s stock worth $138,000 after buying an additional 25,378 shares in the last quarter. Finally, Barclays PLC increased its holdings in Lifecore Biomedical by 301.7% in the 3rd quarter. Barclays PLC now owns 29,944 shares of the company’s stock valued at $147,000 after buying an additional 22,489 shares during the period. Institutional investors own 83.36% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on LFCR. Craig Hallum lifted their target price on shares of Lifecore Biomedical from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 22nd. Stephens reaffirmed an “equal weight” rating and issued a $6.00 price target on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.